When you have asthma, you may have different health care providers who help you manage your asthma. These may include a primary care doctor, specialists and other experts who oversee parts of your treatment plan. Since proper asthma management is key, you need to understand each one’s focus and the role they play in your care. This is the first step toward building a partnership with your health care team for the best quality of life possible.
When you hear about medical research, you probably hear about an organization called the NIH. The NIH is the United States’ medical research agency. It is also one of the top medical research agencies in the world.
Shopping for someone with asthma and allergies this holiday season? Products to help them reduce asthma and allergy triggers make great gifts. Look for Certified asthma & allergy friendly® products this holiday season.
We are thankful for you! Thanks to people like you, adults with asthma and allergies, and families raising children with asthma and allergies, have hope for this holiday season.
Did you know that you can shop on Amazon and support the Asthma and Allergy Foundation (AAFA) at the same time? Amazon has two programs that allow you to shop for your favorite products that will benefit AAFA at no cost to you.
Holiday decorations make your home fun and festive. But they can also bring in asthma triggers and allergens. How do you deck the halls while keeping a healthy home? Here are five asthma & allergy friendly® tips for a healthier home for the holidays.
The Asthma and Allergy Foundation of America (AAFA) believes your voice is valuable part of asthma research. And we want to empower people with asthma, caregivers and health care providers to take an active role in research. Promoting Asthma Patient Engagement in Research (PAPER) is a new research project from AAFA and the Patient-Centered Outcomes Research Institute (PCORI). Through this project, you can influence research that improves asthma understanding and treatment.
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.